Overview

Open Label Study of the Effects of Secukinumab on Nail Psoriasis and Non-Invasive Measures of Enthesitis (Phase IV)

Status:
Not yet recruiting

Trial end date:
2024-09-01

Target enrollment:

Participant gender:

Summary

This study will be an open label study of secukinumab for the treatment of nail psoriasis. Secukinumab is an FDA-approved treatment for psoriasis. We will examine time to response and different methods of defining nail disease response.

Phase:

Phase 4

Details

Lead Sponsor:

University of Pennsylvania

Collaborator:

Novartis